Patents by Inventor Reinaldo Jones

Reinaldo Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 9580449
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: February 28, 2017
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20160264548
    Abstract: The present invention relates to pyridine, pyrimidine, pyrazine, and pyridazine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: October 21, 2014
    Publication date: September 15, 2016
    Applicant: Merck Patent GMBH
    Inventors: Hui QIU, Richard D. CALDWELL, Constantin NEAGU, Igor MOCHALKIN, Lesley LIU-BUJALSKI, Reinaldo JONES, Devon TATE, Theresa L. JOHNSON, Anna GARDBERG
  • PYRIDINES, PYRIMIDINES, AND PYRAZINES, AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20160159804
    Abstract: The present invention relates to pyridine, pyrimidine, and pyrazene compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: July 30, 2014
    Publication date: June 9, 2016
    Inventors: Lesley LIU-BUJALSKI, Ngan NGUYEN, Hui QIU, Reinaldo JONES, Igor MOCHALKIN, Richard D. CALDWELL
  • HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF
    Publication number: 20160145252
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 26, 2016
    Inventors: Catherine JORAND-LEBRUN, Reinaldo JONES, Annie Cho WON, Ngan NGUYEN, Theresa L. JOHNSON, Lizbeth Celeste DESELM, Kausik PANDA
  • HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF
    Publication number: 20160096834
    Abstract: The present invention relates to imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
    Type: Application
    Filed: October 6, 2015
    Publication date: April 7, 2016
    Inventors: Pascale GAILLARD, Jeyaprakashnarayanan SEENISAMY, Lesley LIU-BUJALSKI, Richard D. CALDWELL, Justin POTNICK, Hui QIU, Constantin NEAGU, Reinaldo JONES, Annie Cho WON, Andreas GOUTOPOULOS, Brian A. SHERER, Theresa L. JOHNSON, Anna GARDBERG
  • COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY
    Publication number: 20150259363
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: June 1, 2015
    Publication date: September 17, 2015
    Inventors: Brian L. HODOUS, Lesley LIU-BUJALSKI, Reinaldo JONES, Donald BANKSTON, Theresa L. JOHNSON, Igor MOCHALKIN, Ngan NGUYEN, Hui QIU, Andreas GOUTOPOULOS, Nadia BRUGGER
  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
    Patent number: 9073947
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Grant
    Filed: June 10, 2012
    Date of Patent: July 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Quinazoline carboxamide azetidines
    Patent number: 8946247
    Abstract: The invention provides novel quinazoline carboxamide azetidine compounds according to Formula (I) and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: February 3, 2015
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Reinaldo Jones, Yufang Xiao, Constantin Neagu, Donald Bankston, Andreas Goutopoulos
  • Compositions and Methods for the Production of Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity
    Publication number: 20140162983
    Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.
    Type: Application
    Filed: June 10, 2012
    Publication date: June 12, 2014
    Applicant: Merck Patent GmbH
    Inventors: Brian L. Hodous, Lesley Liu-Bujalski, Reinaldo Jones, Donald Bankston, Theresa L. Johnson, Igor Mochalkin, Ngan Nguyen, Hui Qiu, Andreas Goutopoulos, Nadia Brugger
  • Bicyclic azaheterocyclic carboxamides
    Patent number: 8710044
    Abstract: The invention provides novel bicyclic azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 29, 2014
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Constantin Neagu, Reinaldo Jones, Lizbeth Celeste DeSelm, Yufang Xiao, Srinivasa R. Karra, Ruoxi Lan, Igor Mochalkin, Amanda E. Sutton, Thomas E. Richardson
  • Amino azaheterocyclic carboxamides
    Patent number: 8637532
    Abstract: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: January 28, 2014
    Assignee: Merck Patent GmbH
    Inventors: Amanda E. Sutton, Ruoxi Lan, Thomas E. Richardson, David Perrey, Harold George Vandeveer, Bayard R. Huck, Srinivasa R. Karra, Xiaoling Chen, Yufang Xiao, Lesley Liu-Bujalski, Andreas Goutopoulos, Frank Stieber, Brian L. Hodous, Hui Qiu, Reinaldo Jones, Brian H. Heasley
  • Bicyclic urea compounds
    Patent number: 8569295
    Abstract: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Grant
    Filed: July 28, 2010
    Date of Patent: October 29, 2013
    Assignee: Merck Patent GmbH
    Inventors: Xiaoling Chen, Srinivasa R. Karra, Bayard R. Huck, Ruoxi Lan, Amanda E. Sutton, Andreas Goutopoulos, Brian L. Hodous, Reinaldo Jones
  • QUINAZOLINE CARBOXAMIDE AZETIDINES
    Publication number: 20130252942
    Abstract: The invention provides novel quinazoline carboxamide azetidine compounds according to Formula (I) and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: November 11, 2011
    Publication date: September 26, 2013
    Inventors: Bayard R. Huck, Reinaldo Jones, Yufang Xiao, Constantin Neagu, Donald Bankston, Andreas Goutopoulos
  • Cyclic Amine Azaheterocyclic Carboxamides
    Publication number: 20130217709
    Abstract: The invention provides novel cyclic amine azaheterocyclic carboxamide according to Formula (I), Formula (II) and Formula (III) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: July 28, 2011
    Publication date: August 22, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Bayard R. Huck, Xiaoling Chen, Constantin Neagu, Reinaldo Jones, Yufang Xiao, Igor Mochalkin
  • Bicyclic Azaheterocyclic Carboxamides
    Publication number: 20130137677
    Abstract: The invention provides novel bicyclic azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: July 1, 2011
    Publication date: May 30, 2013
    Applicant: MERCK PATENT GMBH
    Inventors: Bayard R. Huck, Constantin Neagu, Reinaldo Jones, Lizbeth Celeste DeSelm, Yufang Xiao, Srinivasa R. Karra, Ruoxi Lan, Igor Mochalkin, Amanda E. Sutton, Thomas E. Richardson
  • NOVEL BICYCLIC UREA COMPOUNDS
    Publication number: 20120190654
    Abstract: The invention provides novel substituted azaheterocyclic compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: July 28, 2010
    Publication date: July 26, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Xiaoling Chen, Srinivasa R. Karra, Bayard R. Huck, Ruoxi Lan, Amanda E. Sutton, Andreas Goutopoulos, Brian L. Hodous, Reinaldo Jones